Theodore A. Omachi

Pulmonary Medicine | Intensive Care Medicine

3333 California St
Ucsf, Suite 270
San Francisco, CA 94118

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 36 publications

Obinutuzumab or Tacrolimus in Primary Membranous Nephropathy.

Obinutuzumab or Tacrolimus in Primary Membranous Nephropathy.

Journal: The New England journal of medicine

Published: June 05, 2026

Phase Ib, multicentre, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of subcutaneously administered mosunetuzumab in participants with systemic lupus erythematosus.

Phase Ib, multicentre, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of subcutaneously administered mosunetuzumab in participants with systemic lupus erythematosus.

Journal: Lupus science & medicine

Published: February 18, 2026

Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis.

Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis.

Journal: The New England journal of medicine

Published: February 10, 2025

Model-based comparisons of post-treatment free IgE and FEV1 between omalizumab asthma dosing tables in the United States and European Union.

Model-based comparisons of post-treatment free IgE and FEV1 between omalizumab asthma dosing tables in the United States and European Union.

Journal: British journal of clinical pharmacology

Published: April 05, 2024

Meaningful changes for efficacy outcomes in patients with chronic rhinosinusitis with nasal polyps.

Meaningful changes for efficacy outcomes in patients with chronic rhinosinusitis with nasal polyps.

Journal: The World Allergy Organization journal

Published: November 17, 2022

Usage of long-acting muscarinic antagonists and biologics as add-on therapy for patients in the United States with moderate-to-severe asthma.

Usage of long-acting muscarinic antagonists and biologics as add-on therapy for patients in the United States with moderate-to-severe asthma.

Journal: The Journal of asthma : official journal of the Association for the Care of Asthma

Published: May 10, 2021

Pharmacokinetics and exposure-efficacy relationships of omalizumab in patients with nasal polyps.

Pharmacokinetics and exposure-efficacy relationships of omalizumab in patients with nasal polyps.

Journal: Pulmonary pharmacology & therapeutics

Published: April 16, 2021

Long-term efficacy and safety of omalizumab for nasal polyposis in an open-label extension study.

Long-term efficacy and safety of omalizumab for nasal polyposis in an open-label extension study.

Journal: The Journal of allergy and clinical immunology

Published: February 04, 2021

Reply.

Reply.

Journal: The Journal of allergy and clinical immunology

Published: September 18, 2020

Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials.

Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials.

Journal: The Journal of allergy and clinical immunology

Published: December 31, 2019

Developing drugs for treatment of atopic dermatitis in children (≥3 months to <18 years of age): Draft guidance for industry.

Developing drugs for treatment of atopic dermatitis in children (≥3 months to <18 years of age): Draft guidance for industry.

Journal: Pediatric dermatology

Published: March 31, 2018

Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE).

Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE).

Journal: Journal of the American Academy of Dermatology

Published: November 06, 2017

Showing 1-12 of 36

Last Updated: 09/26/2026